Skip to main content

QEMISTRY-Dementia

Quantifying and Explaining Mortality associated with psychotropic prescribing in dementia

Project dates: 01/07/2024 - 31/01/2027

Research Team

  • Juan Carlos Bazo Alvarez (Lead Researcher)
  • Martin Knapp
  • Frank Arrojo
  • Jane Ward
  • Nathan Davies
  • Irene Petersen
  • Claudia Cooper
  • Sube Banerjee

Lead Institution

Partners

  • London School of Economics and Political Science
  • University of Nottingham
  • Queen Mary University of London

Up to one in four people-with-dementia are prescribed antipsychotic drugs annually. This is for behaviours that are challenging to them or others, such as agitation or aggression, or for psychosis. In psychosis, a person might see or hear things that others can’t or have unusual ideas or beliefs.

Fifteen years ago, researchers found that people-with-dementia were twice as likely to die from taking antipsychotic drugs as people without dementia. A government report found that 1 in a 100 died because they were prescribed antipsychotics. After a warning in 2009 by the medicine and health regulator, antipsychotic prescribing nearly halved.

To make prescribing safer, those who write prescriptions are asked to check blood pressure and heart rhythm, and do blood tests before starting treatment, and check for side-effects regularly. They are advised to prescribe at the lowest doses for the shortest time possible. But we found that people-with-dementia take antipsychotics for an average of six months – longer than recommended. Worryingly, people from minority ethnic groups and women were prescribed for longer than other groups.

SSCR Mailing list

Join our mailing list

For news, events and updates direct to your inbox

Join our mailing list

Skip to content